FTO and acute myeloid leukemia: FTO is reported to induce the expression of immune checkpoint leukocyte immunoglobulin-like receptor subfamily B 4 (LILRB4), which contributes to T cell suppression and tumor infiltration in AML, leading to immune evasion (115).Upon treatment with decitabine, FTO expression was significantly increased, resulting in decreased m6A abundance in AML cells.